

Holger Jahn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8908018/publications.pdf>

Version: 2024-02-01

114
papers

6,621
citations

57758

44
h-index

64796

79
g-index

118
all docs

118
docs citations

118
times ranked

8973
citing authors

#	ARTICLE	IF	CITATIONS
1	Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment" data from the Dementia Competence Network. Journal of Neural Transmission, 2022, 129, 477-486.	2.8	14
2	Comparative analysis of machine learning algorithms for multi-syndrome classification of neurodegenerative syndromes. Alzheimer's Research and Therapy, 2022, 14, 62.	6.2	9
3	Quantifying progression in primary progressive aphasia with structural neuroimaging. Alzheimer's and Dementia, 2021, 17, 1595-1609.	0.8	22
4	Motor speech disorders in the nonfluent, semantic and logopenic variants of primary progressive aphasia. Cortex, 2021, 140, 66-79.	2.4	10
5	Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 349-356.	1.9	31
6	Clinico-genetic findings in 509 frontotemporal dementia patients. Molecular Psychiatry, 2021, 26, 5824-5832.	7.9	23
7	Predicting disease progression in behavioral variant frontotemporal dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12262.	2.4	4
8	Factors influencing atrophy progression in primary progressive aphasia. Alzheimer's and Dementia, 2021, 17, .	0.8	0
9	Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with <i>C9orf72</i> hexanucleotide repeat expansion. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 503-511.	1.9	33
10	Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. Journal of Proteome Research, 2020, 19, 1310-1318.	3.7	43
11	Atrial Natriuretic Peptide, the Hypothalamic-Pituitary-Adrenal Axis, and Panic Attacks. , 2019, , 177-186.		0
12	Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. Cortex, 2019, 117, 33-40.	2.4	17
13	Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. Journal of Psychiatric Research, 2019, 113, 137-140.	3.1	81
14	Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 4-10.	1.9	96
15	The applause sign in frontotemporal lobar degeneration and related conditions. Journal of Neurology, 2019, 266, 330-338.	3.6	15
16	Therapeutic Drug Monitoring of Naltrexone and ⁶² Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges. Alcohol and Alcoholism, 2019, 54, 51-55.	1.6	2
17	A language-based sum score for the course and therapeutic intervention in primary progressive aphasia. Alzheimer's Research and Therapy, 2018, 10, 41.	6.2	8
18	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	1.9	89

#	ARTICLE	IF	CITATIONS
19	Serum neurofilament light chain in behavioral variant frontotemporal dementia. <i>Neurology</i> , 2018, 91, e1390-e1401.	1.1	85
20	Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. <i>PLoS ONE</i> , 2018, 13, e0197329.	2.5	68
21	A Modified Reading the Mind in the Eyes Test Predicts Behavioral Variant Frontotemporal Dementia Better Than Executive Function Tests. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 11.	3.4	34
22	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients – An Atlas-Based Volumetric MRI Study. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 45.	3.4	40
23	A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. <i>Journal of Psychopharmacology</i> , 2018, 32, 668-677.	4.0	44
24	MicroRNA Profiling of Alzheimer’s Disease Cerebrospinal Fluid. <i>Methods in Molecular Biology</i> , 2018, 1750, 93-107.	0.9	2
25	Alzheimer's disease: Elevated pigment epithelium-derived factor in the cerebrospinal fluid is mostly of systemic origin. <i>Journal of the Neurological Sciences</i> , 2017, 375, 123-128.	0.6	8
26	PolyGP in cerebrospinal fluid links C9orf72-associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD. <i>EMBO Molecular Medicine</i> , 2017, 9, 859-868.	6.9	90
27	Copeptin – A potential endocrine surrogate marker of CCK-4-induced panic symptoms?. <i>Psychoneuroendocrinology</i> , 2017, 76, 14-18.	2.7	9
28	Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 84.	6.2	58
29	Amyloid- β^2 Precursor Protein Modulates the Sorting of Testican-1 and Contributes to Its Accumulation in Brain Tissue and Cerebrospinal Fluid from Patients with Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 903-916.	1.7	18
30	Steroid-synthesis inhibition in depression: a good idea?. <i>Lancet Psychiatry</i> , 2016, 3, 92-93.	7.4	3
31	Nonfluent Variant of Primary Progressive Aphasia With Right Hemisphere Atrophy – A Phenotype of Corticobasal Degeneration?. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 420-421.	1.5	0
32	The Latent Dementia Phenotype \hat{I} is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 547-560.	2.6	23
33	MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer’s Disease. <i>PLoS ONE</i> , 2015, 10, e0126423.	2.5	184
34	Investigations on CXCL13 in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. <i>JAMA Neurology</i> , 2015, 72, 180.	9.0	142
35	Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. <i>Neurobiology of Aging</i> , 2015, 36, 601-607.	3.1	125
36	Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI. <i>Neurology</i> , 2015, 84, 1261-1268.	1.1	41

#	ARTICLE	IF	CITATIONS
37	Overnight suppression of HPA axis after mineralocorticoid receptor stimulation: A sleep endocrine study. <i>Psychiatry Research</i> , 2015, 227, 65-70.	3.3	2
38	Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer's disease: a voxel-based lesion mapping study. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 27.	6.2	13
39	Memory Concerns, Memory Performance and Risk of Dementia in Patients with Mild Cognitive Impairment. <i>PLoS ONE</i> , 2014, 9, e100812.	2.5	41
40	A novel computerized algorithm to detect microstructural brainstem pathology in Parkinson's disease using standard 3 Tesla MR imaging. <i>Journal of Neurology</i> , 2014, 261, 1968-1975.	3.6	1
41	Intraperitoneal Atrial Natriuretic Peptide Attenuates Anxiety-related Behaviour during Alcohol Withdrawal in Mice. <i>Pharmacopsychiatry</i> , 2014, 47, 97-100.	3.3	8
42	A novel presenilin 1 mutation (Ala275Val) as cause of early-onset familial Alzheimer disease. <i>Neuroscience Letters</i> , 2014, 566, 115-119.	2.1	7
43	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. <i>Neurobiology of Aging</i> , 2014, 35, 2657.e13-2657.e19.	3.1	34
44	Genetic interaction of <i>PICALM</i> and <i>APOE</i> is associated with brain atrophy and cognitive impairment in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, S269-76.	0.8	47
45	High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 822-832.	3.7	114
46	Memory Concerns, Memory Performance and Risk of Dementia in Patients with Mild Cognitive Impairment. , 2014, 9, e100812.		0
47	Association between fully automated MRI-based volumetry of different brain regions and neuropsychological test performance in patients with amnesic mild cognitive impairment and Alzheimer's disease. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 335-344.	3.2	42
48	Mirtazapine-Induced Galactorrhea: A Case Report. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2013, 25, E13-E14.	1.8	5
49	Genetic Risk Factors for Depression in Alzheimer's Disease Patients. <i>Current Alzheimer Research</i> , 2013, 10, 72-81.	1.4	5
50	No Effects of Antidepressants on Negative Symptoms in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 686-690.	1.4	23
51	APOE-Dependent Phenotypes in Subjects with Mild Cognitive Impairment Converting to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 389-401.	2.6	13
52	Memory loss in Alzheimer's disease. <i>Dialogues in Clinical Neuroscience</i> , 2013, 15, 445-454.	3.7	393
53	Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone. <i>World Journal of Biological Psychiatry</i> , 2012, 13, 526-534.	2.6	5
54	Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. <i>Neurology</i> , 2012, 78, 379-386.	1.1	141

#	ARTICLE	IF	CITATIONS
55	Use of proteomic methods in the analysis of human body fluids in Alzheimer research. Electrophoresis, 2012, 33, 3617-3630.	2.4	35
56	Dimethylarginines, Homocysteine Metabolism, and Cerebrospinal Fluid Markers for Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 31, 751-758.	2.6	32
57	Recent advances in structural MRI in Parkinson's disease and atypical parkinsonian syndromes. Neurodegenerative Disease Management, 2012, 2, 517-533.	2.2	0
58	A combination of galantamine and memantine modifies cognitive function in subjects with amnesic MCI. Journal of Nutrition, Health and Aging, 2012, 16, 544-548.	3.3	48
59	Peptide Fingerprinting of Alzheimer's Disease in Cerebrospinal Fluid: Identification and Prospective Evaluation of New Synaptic Biomarkers. PLoS ONE, 2011, 6, e26540.	2.5	105
60	Modulation of the mineralocorticoid receptor as add-on treatment in depression: A randomized, double-blind, placebo-controlled proof-of-concept study. Journal of Psychiatric Research, 2010, 44, 339-346.	3.1	115
61	CCK-4: Psychophysiological conditioning elicits features of spontaneous panic attacks. Journal of Psychiatric Research, 2010, 44, 1148-1153.	3.1	16
62	Influence of exogenous atrial natriuretic peptide on the nocturnal hypothalamic-pituitary-adrenal axis and sleep in healthy men. Psychoneuroendocrinology, 2010, 35, 1438-1445.	2.7	4
63	Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Molecular Psychiatry, 2010, 15, 138-145.	7.9	156
64	Augmented Stress-Induced Alcohol Drinking and Withdrawal in Mice Lacking Functional Natriuretic Peptide-A Receptors. Alcohol and Alcoholism, 2010, 45, 13-16.	1.6	15
65	Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Experimental Neurology, 2010, 223, 366-370.	4.1	92
66	B-spline-based stereotactical normalization of brain FDG PET scans in suspected neurodegenerative disease: Impact on voxel-based statistical single-subject analysis. NeuroImage, 2010, 50, 994-1003.	4.2	7
67	Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. Molecular and Cellular Proteomics, 2010, 9, 2424-2437.	3.8	434
68	Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2009, 27, 404-417.	1.5	90
69	A multicenter ¹ H-MRS study of the medial temporal lobe in AD and MCI. Neurology, 2009, 72, 1735-1740.	1.1	72
70	Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1090-1100.	6.4	26
71	Proteomics as a New Tool for Biomarker-Discovery in Neuropsychiatric Disorders. , 2009, , 103-111.		0
72	The patient with dementia, the caregiver and the doctor: cognition, depression and quality of life from three perspectives. International Journal of Geriatric Psychiatry, 2008, 23, 604-610.	2.7	73

#	ARTICLE	IF	CITATIONS
73	Asymmetrical Dimethylarginine Is Increased in Plasma and Decreased in Cerebrospinal Fluid of Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 58-64.	1.5	51
74	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. <i>Neurobiology of Aging</i> , 2008, 29, 812-818.	3.1	94
75	Capillary electrophoresis mass spectrometry as a potential tool to detect lithium-induced nephropathy: Preliminary results. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 673-678.	4.8	7
76	Amyloid β peptide ratio 42/40 but not $A\beta_{42}$ correlates with phospho τ in patients with low- and high-CSF $A\beta_{40}$ load. <i>Journal of Neurochemistry</i> , 2007, 101, 1053-1059.	3.9	237
77	Hypothalamic-Pituitary-Adrenocortical Axis Activity: A Target of Pharmacological Anticraving Treatment?. <i>Biological Psychiatry</i> , 2006, 60, 74-76.	1.3	60
78	Effects of treatment with acamprosate on β -endorphin plasma concentration in humans with high alcohol preference. <i>Neuroscience Letters</i> , 2006, 404, 103-106.	2.1	21
79	Pharmacological treatment of non-Alzheimer dementias. <i>Current Opinion in Psychiatry</i> , 2006, 19, 642-648.	6.3	4
80	Megestrol attenuates the hormonal response to CCK-4-induced panic attacks. <i>Depression and Anxiety</i> , 2006, 23, 139-144.	4.1	7
81	Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism. <i>Journal of Psychiatric Research</i> , 2005, 39, 545-551.	3.1	72
82	Pharmacological Relapse Prevention of Alcoholism: Clinical Predictors of Outcome. <i>European Addiction Research</i> , 2005, 11, 83-91.	2.4	96
83	Uso auxiliar de la reboxetina en la esquizofrenia. <i>European Psychiatry (Ed Espa�ola)</i> , 2005, 12, 107-110.	0.0	0
84	Metyrapone as Additive Treatment in Major Depression. <i>Archives of General Psychiatry</i> , 2004, 61, 1235.	12.3	163
85	Dimensional structure of the Hamilton Depression Rating Scale in patients with obsessive-compulsive disorder. <i>Psychiatry Research</i> , 2004, 125, 171-180.	3.3	44
86	Overnight metyrapone and combined dexamethasone/metyrapone tests in post-traumatic stress disorder: preliminary findings. <i>European Neuropsychopharmacology</i> , 2004, 14, 337-339.	0.7	14
87	Adjunctive use of reboxetine in schizophrenia. <i>European Psychiatry</i> , 2004, 19, 366-369.	0.2	27
88	Acute effects of megestrol on the hypothalamic-pituitary-adrenal axis. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 482-486.	2.3	10
89	Modulation of sympathetic activity by corticotropin-releasing hormone and atrial natriuretic peptide. <i>Neuropeptides</i> , 2003, 37, 362-368.	2.2	49
90	Involvement of NMDA receptors in alcohol-mediated behavior: mice with reduced affinity of the NMDA R1 glycine binding site display an attenuated sensitivity to ethanol. <i>Biological Psychiatry</i> , 2003, 53, 345-351.	1.3	41

#	ARTICLE	IF	CITATIONS
91	The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone. <i>Life Sciences</i> , 2003, 73, 1835-1845.	4.3	48
92	Natriuretic peptides and panic disorder: therapeutic prospects. <i>Expert Review of Neurotherapeutics</i> , 2003, 3, 381-386.	2.8	9
93	Mineralocorticoid Receptor-Mediated Inhibition of the Hypothalamic-Pituitary-Adrenal Axis in Aged Humans. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2003, 58, B900-B905.	3.6	46
94	Impact of comorbid depressive symptoms on nonverbal memory and visuospatial performance in obsessive-compulsive disorder. <i>Cognitive Neuropsychiatry</i> , 2003, 8, 261-272.	1.3	66
95	Comparing and Combining Naltrexone and Acamprosate in Relapse Prevention of Alcoholism. <i>Archives of General Psychiatry</i> , 2003, 60, 92.	12.3	386
96	Sleep Endocrine Effects of the 11- β -Hydroxysteroiddehydrogenase Inhibitor Metyrapone. <i>Sleep</i> , 2003, 26, 823-829.	1.1	21
97	Executive functioning in obsessive-compulsive disorder, unipolar depression, and schizophrenia. <i>Archives of Clinical Neuropsychology</i> , 2002, 17, 477-483.	0.5	73
98	Prolactin but not ACTH increases during sodium lactate-induced panic attacks. <i>Psychiatry Research</i> , 2002, 109, 201-205.	3.3	14
99	Is withdrawal-induced anxiety in alcoholism based on β -endorphin deficiency?. <i>Psychopharmacology</i> , 2002, 162, 433-437.	3.1	50
100	Alcohol self-administration, craving and HPA-axis activity: an intriguing relationship. <i>Psychopharmacology</i> , 2002, 164, 239-240.	3.1	48
101	Leptin: a modulator of alcohol craving?. <i>Biological Psychiatry</i> , 2001, 49, 782-787.	1.3	116
102	Disruption of ClC-3, a Chloride Channel Expressed on Synaptic Vesicles, Leads to a Loss of the Hippocampus. <i>Neuron</i> , 2001, 29, 185-196.	8.1	480
103	Leptin as a Possible Modulator of Craving for Alcohol. <i>Archives of General Psychiatry</i> , 2001, 58, 509.	12.3	55
104	Anxiolyticlike Effects of Atrial Natriuretic Peptide on Cholecystokinin Tetrapeptide-Induced Panic Attacks. <i>Archives of General Psychiatry</i> , 2001, 58, 371.	12.3	86
105	β -Helical-corticotropin-releasing hormone reverses anxiogenic effects of C-type natriuretic peptide in rats. <i>Brain Research</i> , 2001, 893, 21-28.	2.2	14
106	Elevation of β -Amyloid Peptide 25-42 in Sporadic and Familial Alzheimer's Disease and Its Generation in PS1 Knockout Cells. <i>Journal of Biological Chemistry</i> , 2001, 276, 42645-42657.	3.4	115
107	Harman and norharman plasma levels in weaned alcoholics: correlations with depression and tobacco smoking. <i>Addiction Biology</i> , 2000, 5, 437-441.	2.6	4
108	Centrifugal Phe-Met-Arg-Phe-NH ₂ -like immunoreactive innervation of the retina in a non-teleost bony fish, <i>Lepisosteus osseus</i> . <i>Neuroscience Letters</i> , 1999, 264, 33-36.	2.1	16

#	ARTICLE	IF	CITATIONS
109	C-type natriuretic peptide exerts effects opposing those of atrial natriuretic peptide on anxiety-related behaviour in rats. <i>Brain Research</i> , 1998, 792, 358-360.	2.2	25
110	Atrial natriuretic hormone in lactate-induced panic attacks: mode of release and endocrine and pathophysiological consequences. <i>Journal of Psychiatric Research</i> , 1998, 32, 37-48.	3.1	36
111	Suicide attempts with mirtazapine overdose without complications. <i>Biological Psychiatry</i> , 1998, 44, 925-926.	1.3	33
112	C-type natriuretic peptide exerts stimulatory effects on the corticotropin-releasing hormone-induced secretion of hormones in normal man. <i>European Journal of Endocrinology</i> , 1997, 136, 388-393.	3.7	16
113	Central and Peripheral Administration of Atriopeptin Is Anxiolytic in Rats. <i>Neuroendocrinology</i> , 1997, 65, 210-215.	2.5	54
114	Site-specific phosphorylation of the purified receptor for calcium-channel blockers by cAMP- and cGMP-dependent protein kinases, protein kinase C, calmodulin-dependent protein kinase II and casein kinase II. <i>FEBS Journal</i> , 1988, 178, 535-542.	0.2	120